HOME
MEDICATIONS
PROGRAM SUPPLEMENTS
ABOUT US CONTACT
HOME
MEDICATIONS
PROGRAM SUPPLEMENTS
ABOUT US CONTACT
If
you want to taper off the Pristiq and you are not sure where to start, you can
click here and read the bestselling book, How to Get
Off Psychoactive Drugs Safely or send Jim Harper an email at
Jim@theroadback.org and he will guide you through the process of Pristiq
withdrawal.
If you
are experiencing brain zaps, electrical jolts in the head,
click here
If
you are already in Pristiq withdrawal click here
Pristiq (desvenlafaxine) is a prescription medication used to treat major
depressive disorder (MDD) in adults. It belongs to the class of drugs known as
serotonin-norepinephrine reuptake inhibitors (SNRIs). Pristiq works by
increasing the levels of certain chemicals in the brain that help regulate mood,
such as serotonin and norepinephrine.
Like
all medications, Pristiq can cause side effects. One of the most common side
effects of Pristiq is withdrawal symptoms that occur when the medication is
stopped abruptly. Withdrawal symptoms can also occur when a patient misses a
dose of Pristiq.
The
severity of Pristiq withdrawal symptoms can vary from person to person. Some
individuals may experience mild symptoms, while others may experience severe
symptoms that can interfere with their daily activities.
Common
Pristiq withdrawal symptoms
include:DizzinessNauseaHeadachesFatigueInsomniaIrritabilityAnxietySweatingTingling
or numbness in the hands or feet.
Flu-like symptoms, such as chills and body ache In addition to these common
symptoms, some individuals may experience more severe withdrawal symptoms, such
as:
Suicidal thoughts or behavior
Mania
or hypomania (symptoms of bipolar disorder)
Seizures
Hallucinations
Delirium
If you
experience any of these severe symptoms, seek immediate medical attention.
Pristiq withdrawal can be challenging, but there are steps you can take to
minimize the severity of symptoms. It is important to work with your healthcare
provider to develop a plan for tapering off Pristiq slowly. Tapering involves
gradually reducing the dosage of Pristiq over a period of several weeks or
months, which allows your body to adjust to the changes in the medication.
The
JNK gene, also known as MAPK8, encodes for the JNK protein, which belongs to the
mitogen-activated protein kinase (MAPK) family. JNK is activated in response to
various stress stimuli, such as oxidative stress, inflammation, and DNA damage.
Once activated, JNK triggers a signaling cascade that leads to the activation of
transcription factors, which regulate the expression of genes involved in cell
proliferation, differentiation, and apoptosis.
Recent
studies have shown that Pristiq can modulate the activity of the JNK pathway. In
particular, Pristiq has been shown to inhibit the activity of JNK3, one of the
three isoforms of JNK. This inhibition leads to a reduction in the activation of
transcription factors that are downstream of JNK, such as c-Jun and ATF-2. As a
result, the expression of genes involved in inflammation and cell death is
reduced.
In
addition to its effects on the JNK pathway, Pristiq also modulates other
signaling pathways involved in the pathophysiology of depression and anxiety.
For example, Pristiq inhibits the reuptake of both serotonin and norepinephrine,
which are neurotransmitters involved in the regulation of mood, sleep, and
appetite. By increasing the availability of these neurotransmitters in the
brain, Pristiq can improve mood, reduce anxiety, and alleviate other symptoms of
depression and anxiety disorders.
The
exact mechanisms by which Pristiq modulates the JNK pathway are still under
investigation. However, it is thought that Pristiq may act through the
inhibition of the activity of certain enzymes, such as glycogen synthase
kinase-3β (GSK-3β), that are involved in the regulation of JNK activity. By
inhibiting GSK-3β, Pristiq may indirectly inhibit the activity of JNK, leading
to a reduction in the expression of genes involved in inflammation and cell
death.
In
conclusion, Pristiq is a medication that has been shown to modulate the activity
of the JNK pathway, a signaling cascade involved in inflammation and cell death.
By inhibiting the activity of JNK3, Pristiq can reduce the activation of
transcription factors that regulate the expression of genes involved in these
processes. This mechanism of action, combined with Pristiq's effects on other
signaling pathways involved in the pathophysiology of depression and anxiety,
makes Pristiq an effective treatment option for these conditions. However,
further research is needed to fully understand the exact mechanisms by which
Pristiq modulates the JNK pathway and to identify potential therapeutic targets
for the treatment of depression and anxiety disorders.
Pristiq and Obesity
Obesity is a growing problem worldwide and is associated with a variety of
health problems, such as cardiovascular disease, diabetes, and certain types of
cancer. There are many factors that can contribute to the development of
obesity, including genetics, lifestyle, and environmental factors. Medications
can also contribute to weight gain, and Pristiq is one such medication.
Studies have shown that Pristiq can cause weight gain in some individuals. In
one study, patients taking Pristiq for 24 weeks gained an average of 1.1
kilograms (2.4 pounds) of weight, while those taking a placebo gained an average
of 0.1 kilograms (0.2 pounds). Another study found that patients taking Pristiq
for 12 weeks gained an average of 1.5 kilograms (3.3 pounds) of weight, compared
to an average weight loss of 0.3 kilograms (0.7 pounds) in those taking a
placebo.
The
exact mechanism by which Pristiq causes weight gain is not fully understood.
However, it is thought to be related to its effects on certain neurotransmitters
in the brain. Serotonin and norepinephrine are two neurotransmitters that are
involved in the regulation of appetite and metabolism. By increasing the
availability of these neurotransmitters, Pristiq may lead to an increase in
appetite and a decrease in metabolism, which can contribute to weight gain.
While
weight gain can be a concern for individuals taking Pristiq, it is important to
note that not everyone who takes the medication will experience this side
effect. Additionally, the amount of weight gain can vary from person to person.
For some individuals, the weight gain may be minimal and not a cause for
concern, while for others, it may be more significant and require intervention.
Metabolic Disorders>Pristiq and metabolic disorder, on the other hand, refers to
a cluster of conditions that affect the body's ability to metabolize nutrients
properly. These conditions include obesity, insulin resistance, high blood
pressure, and high cholesterol levels. Metabolic disorders can increase the risk
of developing type 2 diabetes, cardiovascular disease, and other health
problems.
Recent
studies have suggested a potential link between Pristiq use and metabolic
disorders. In particular, research has shown that Pristiq can cause weight gain,
which is a known risk factor for metabolic disorders.
1. NAMI authors, “Desvenlafaxine (Pristiq)” National Alliance on Mental Illness [online publication] December 2018 [cited 2022 July 27]
2. Zhang, G., Gao, Z., Guan, S. et al. “Upregulation of excitatory neurons and downregulation of inhibitory neurons in barrel cortex are associated with loss of whisker inputs.” Mol Brain6,&2 (2013). https://doi.org/10.1186/1756-6606-6-2 [cited 2022 July 27]
3. Guzman F MD “Venlafaxine and Desvenlafaxine: Differences and Similarities” Psychopharmacology Institute, 2019 Jun 27 [cited 2022 July 27]
4. FDA drug label Pristiq (desvenlafaxine) 2008 [cited 2022 July 27]
5. Papp A, Onton JA. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. Prim Care Companion CNS Disord. 2018 Dec 20;20(6):18m02311. doi: 10.4088/PCC.18m02311. PMID: 30605268. [cited 2022 July 27]
6. Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017;356:j603. Published 2017 Feb 21. doi:10.1136/bmj.j603 [cited 2022 July 27]
7. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997;58 Suppl 7:37-40. PMID: 9219493. [cited 2022 July 27]
8. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int. 2019;116(20):355-361. doi:10.3238/arztebl.2019.0355 [cited 2021 Jun 14]
9. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. 2017;189(21):E747. doi:10.1503/cmaj.160991 [cited 2022 July 27]
10. Berber MJ. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation). J Clin Psychiatry. 1998 May;59(5):255. PMID: 9632038. [cited 2022 July 27]
11. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry. 1984 Feb;19(2):237-56. PMID: 6324897. [cited 2022 July 27]
12. Dilsaver SC, Kronfol Z, Sackellares JC, Greden JF. Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol. 1983 Jun;3(3):157-64. PMID: 6348107. [cited 2021 Jun 14]
13. Wolfe RM. Antidepressant withdrawal reactions. Am Fam Physician. 1997 Aug;56(2):455-62. Erratum in: Am Fam Physician 1998 Feb 15;57(4):646. PMID: 9262526. [cited 2022 July 27]
14. Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010 Jul;48(7):9-12. doi: 10.3928/02793695-20100527-98. Epub 2010 Jun 22. PMID: 20608581. [cited 2022 July 27]
15. Naseeruddin R, Rosani A, Marwaha R. Desvenlafaxine. [Updated 2021 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534829/ [cited 2022 July 27]
16. Skanland S, Cieslar Pobuda A, “Off-label uses of drugs for depression.” European Journal of Pharmacology Vol 865, 15 December 2019, 172732 as published in Science Direct [cited 2022 July 27]
17. Liebowitz MR, Tourian KA. Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09r00845. doi:10.4088/PCC.09r00845blu [cited 2022 July 27]
18. Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr;31(4):809-20. doi: 10.1185/03007995.2015.1020365. Epub 2015 Mar 26. PMID: 25758058. [cited 2022 July 27]